Diabetic retinopathy: management and monitoring

For a short explanation of why the committee made this recommendation for research, see the rationale section on when to add, switch or stop treatment.

Full details of the evidence and the committee's discussion are in evidence review H: clinical features or factors that suggest treatment should be switched or stopped for people diagnosed with proliferative diabetic retinopathy or diabetic macular oedema.

For a short explanation of why the committee made this recommendation for research, see the rationale section on information that should be available to all people involved in the care of people with diabetic retinopathy.

Full details of the evidence and the committee's discussion are in evidence review A: prognostic factors for progression of non-proliferative diabetic retinopathy.

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy.

Full details of the evidence and the committee's discussion are in evidence review E: effectiveness and acceptability of anti-VEGFs and laser photocoagulation (alone or in combination) for the treatment of non-proliferative and proliferative diabetic retinopathy.

For a short explanation of why the committee made this recommendation for research, see the rationale section on effects of a rapid reduction in HbA1c.

Full details of the evidence and the committee's discussion are in evidence review C: effectiveness of intensive treatments to lower blood glucose levels.

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy.

Full details of the evidence and the committee's discussion are in evidence review E: effectiveness and acceptability of anti-VEGFs and laser photocoagulation (alone or in combination) for the treatment of non-proliferative and proliferative diabetic retinopathy.

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy.

Full details of the evidence and the committee's discussion are in evidence review B: different thresholds or criteria for starting treatment for non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular oedema.

For a short explanation of why the committee made this recommendation for research, see the rationale section on statins.

Full details of the evidence and the committee's discussion are in evidence review D: effectiveness of lipid modification therapies and antihypertensive medicines.

For a short explanation of why the committee made this recommendation for research, see the rationale section on fenofibrate.

Full details of the evidence and the committee's discussion are in evidence review D: effectiveness of lipid modification therapies and antihypertensive medicines.

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy.

Full details of the evidence and the committee's discussion are in evidence review E: effectiveness and acceptability of anti-VEGFs and laser photocoagulation (alone or in combination) for the treatment of non-proliferative and proliferative diabetic retinopathy.

For a short explanation of why the committee made this recommendation for research, see the rationale section on cataract surgery.

Full details of the evidence and the committee's discussion are in evidence review I: treatments before, during or after cataract surgery.

For a short explanation of why the committee made this recommendation for research, see the rationale section on cataract surgery.

Full details of the evidence and the committee's discussion are in evidence review I: treatments before, during or after cataract surgery.

For a short explanation of why the committee made this recommendation for research, see the rationale section on when to assess disease status and how often to monitor.

Full details of the evidence and the committee's discussion are in evidence review J: effectiveness of different monitoring frequencies.

For a short explanation of why the committee made this recommendation for research, see the rationale section on when to assess disease status and how often to monitor.

Full details of the evidence and the committee's discussion are in evidence review J: effectiveness of different monitoring frequencies.

For a short explanation of why the committee made this recommendation for research, see the rationale section on imaging techniques for monitoring diabetic retinopathy and diabetic macular oedema.

Full details of the evidence and the committee's discussion are in evidence review K: diagnostic accuracy of ultrawide-field fundus photography and optical coherence tomography.